Sagimet Biosciences Inc [SGMT] stock is trading at $5.31, down -0.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The SGMT shares have gain 7.71% over the last week, with a monthly amount drifted -0.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on November 12, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $12. Previously, Goldman downgraded its rating to Neutral on June 28, 2024, and dropped its price target to $6. On May 02, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $32 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $26 on March 25, 2024. TD Cowen initiated its recommendation with a Outperform. Piper Sandler started tracking with a Overweight rating for this stock on August 08, 2023, and assigned it a price target of $67. In a note dated August 08, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $30 on this stock.
Sagimet Biosciences Inc [SGMT] stock has fluctuated between $2.39 and $20.71 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $5.31 at the most recent close of the market. An investor can expect a potential return of 12.99% based on the average SGMT price forecast.
Analyzing the SGMT fundamentals
Sagimet Biosciences Inc [NASDAQ:SGMT] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.24 and Total Capital is -0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.16 points at the first support level, and at 5.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.47, and for the 2nd resistance point, it is at 5.64.
Ratios To Look Out For
For context, Sagimet Biosciences Inc’s Current Ratio is 38.34. On the other hand, the Quick Ratio is 38.34, and the Cash Ratio is 18.82.
Transactions by insiders
Recent insider trading involved Kemble George, Executive Chairman, that happened on Jul 23 ’24 when 23625.0 shares were sold. Chief Medical Officer, Martins Eduardo Bruno completed a deal on Jul 19 ’24 to sell 8357.0 shares. Meanwhile, General Counsel and CCO Rozek Elizabeth sold 10914.0 shares on Jul 19 ’24.
